Literature DB >> 15210703

Transformation potential of Ras isoforms correlates with activation of phosphatidylinositol 3-kinase but not ERK.

Weiquan Li1, Tianqing Zhu, Kun-Liang Guan.   

Abstract

The Ras oncoproteins activate the Raf-MEK-ERK kinase pathway, which plays an important role in cellular transformation. We observed that H-RasV12 exhibited a higher transforming potential than either K-RasV12 or N-RasV12 in both NIH3T3 fibroblasts and RIE-1 rat epithelial cell cultures. Surprisingly N-Ras and K-Ras were more potent than H-Ras in activation of mitogen-activated protein (MAP) kinase activity and ternary complex factor-dependent transcription. In contrast, H-Ras was more effective in activation of phosphatidylinositol 3-kinase (PI3K) and AKT. Co-expression of constitutively active AKT, a downstream target of PI3K, cooperated with H-RasV12, K-RasV12, or N-RasV12 in transformation. Furthermore co-expression of the constitutively active MEK and AKT resulted in focus formation, while neither active MEK1 nor active AKT alone transformed NIH3T3 cells. Our data demonstrated that the transforming potential of Ras was not directly correlated with the ability of Ras to activate the MAP kinase cascade. In contrast, the ability to activate PI3K and AKT correlated with the ability of Ras to induce cellular transformation, suggesting an important role of PI3K-AKT in cellular transformation. Our data also demonstrated that, under these assay conditions, activation of the MAP kinase cascade was not sufficient to induce NIH3T3 cell transformation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210703     DOI: 10.1074/jbc.M405730200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  Characterization of KRAS rearrangements in metastatic prostate cancer.

Authors:  Xiao-Song Wang; Sunita Shankar; Saravana M Dhanasekaran; Bushra Ateeq; Atsuo T Sasaki; Xiaojun Jing; Daniel Robinson; Qi Cao; John R Prensner; Anastasia K Yocum; Rui Wang; Daniel F Fries; Bo Han; Irfan A Asangani; Xuhong Cao; Yong Li; Gilbert S Omenn; Dorothee Pflueger; Anuradha Gopalan; Victor E Reuter; Emily Rose Kahoud; Lewis C Cantley; Mark A Rubin; Nallasivam Palanisamy; Sooryanarayana Varambally; Arul M Chinnaiyan
Journal:  Cancer Discov       Date:  2011-06-01       Impact factor: 39.397

2.  Compartmentalized Ras proteins transform NIH 3T3 cells with different efficiencies.

Authors:  Chiang-Min Cheng; Huiling Li; Stéphane Gasman; Jian Huang; Rachel Schiff; Eric C Chang
Journal:  Mol Cell Biol       Date:  2010-12-28       Impact factor: 4.272

Review 3.  Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

Authors:  James A McCubrey; Stephen L Abrams; Kristin Stadelman; William H Chappell; Michelle Lahair; Richard A Ferland; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2009-11-04

4.  Palmitoylation of oncogenic NRAS is essential for leukemogenesis.

Authors:  Benjamin Cuiffo; Ruibao Ren
Journal:  Blood       Date:  2010-03-03       Impact factor: 22.113

Review 5.  Chemistry and biology of the compounds that modulate cell migration.

Authors:  Etsu Tashiro; Masaya Imoto
Journal:  J Ind Microbiol Biotechnol       Date:  2015-07-15       Impact factor: 3.346

Review 6.  PI3K: A Crucial Piece in the RAS Signaling Puzzle.

Authors:  Agata Adelajda Krygowska; Esther Castellano
Journal:  Cold Spring Harb Perspect Med       Date:  2018-06-01       Impact factor: 6.915

7.  Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt.

Authors:  David Romano; David Matallanas; Gregory Weitsman; Christian Preisinger; Tony Ng; Walter Kolch
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

8.  FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

Authors:  Lucie C Kompier; Irene Lurkin; Madelon N M van der Aa; Bas W G van Rhijn; Theo H van der Kwast; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

9.  GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling.

Authors:  Emira Ayroldi; Ornella Zollo; Alessandra Bastianelli; Cristina Marchetti; Massimiliano Agostini; Rosa Di Virgilio; Carlo Riccardi
Journal:  J Clin Invest       Date:  2007-05-10       Impact factor: 14.808

10.  Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity.

Authors:  Juxiang Cao; Jennifer Schulte; Alexander Knight; Nicholas R Leslie; Agnieszka Zagozdzon; Roderick Bronson; Yefim Manevich; Craig Beeson; Carola A Neumann
Journal:  EMBO J       Date:  2009-04-16       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.